Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

To effectively battle cancer, scientists must study the battlefield. Now, in a recent study published in Nature ...

The cancer microenvironment, or tumour microenvironment, describes the non-cancerous cells present in the tumour. These include fibroblasts, immune cells and cells that comprise the blood vessels.

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

Researchers found that the Wnt5a protein, secreted by inflammatory fibroblasts within cancerous tumors, inhibits angiogenesis and consequently promotes hypoxia within tumors. Hypoxic conditions help ...

Focus groups with patients with early-onset colorectal cancer and survivors highlight critical gaps in awareness, diagnostic ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 ...

We conducted this randomized phase III study (JCOG1007, iPACS study; UMIN identifier: UMIN000008147) 16 to evaluate the survival benefit of adding upfront PTR to standard chemotherapy for patients ...